Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ENVB logo ENVB
Upturn stock ratingUpturn stock rating
ENVB logo

Enveric Biosciences Inc (ENVB)

Upturn stock ratingUpturn stock rating
$0.94
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/15/2025: ENVB (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $10

1 Year Target Price $10

Analysts Price Target For last 52 week
$10 Target price
52w Low $0.85
Current$0.94
52w High $8.32

Analysis of Past Performance

Type Stock
Historic Profit -63.49%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/15/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.15M USD
Price to earnings Ratio -
1Y Target Price 10
Price to earnings Ratio -
1Y Target Price 10
Volume (30-day avg) 1
Beta 0.37
52 Weeks Range 0.85 - 8.32
Updated Date 09/15/2025
52 Weeks Range 0.85 - 8.32
Updated Date 09/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -9.97

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -129.73%
Return on Equity (TTM) -261.96%

Valuation

Trailing PE -
Forward PE 23.09
Enterprise Value 298754
Price to Sales(TTM) 0.08
Enterprise Value 298754
Price to Sales(TTM) 0.08
Enterprise Value to Revenue 1.76
Enterprise Value to EBITDA 0.29
Shares Outstanding 3246280
Shares Floating 3222067
Shares Outstanding 3246280
Shares Floating 3222067
Percent Insiders 6.84
Percent Institutions 10.2

ai summary icon Upturn AI SWOT

Enveric Biosciences Inc

stock logo

Company Overview

overview logo History and Background

Enveric Biosciences, Inc., founded in 2014, is a biotechnology company focused on developing novel neuroplastogenic small molecule therapeutics for the treatment of anxiety, depression, and PTSD. It initially focused on cannabinoid-based therapies before shifting its focus to psychedelic-inspired molecules.

business area logo Core Business Areas

  • EVM201 Series: This segment involves the development of molecules designed to promote neuroplasticity and treat mental health disorders. The product includes psilocin prodrugs.
  • Psybrary: This involves the discovery and development of novel psychedelic-inspired molecules using a drug discovery platform.

leadership logo Leadership and Structure

The leadership team includes Joseph Tucker, Ph.D., CEO. The company has a board of directors that oversees strategic direction. The organizational structure is typical of a small biotech company, with research, development, and administrative functions.

Top Products and Market Share

overview logo Key Offerings

  • EVM201 Series: These are novel, patented, prodrugs of psilocin, the active metabolite of psilocybin. These are being developed for the treatment of mental health conditions. Enveric's primary competitors for EVM201 include companies developing similar psilocybin-based therapies, such as COMPASS Pathways (CMPS), and ATAI Life Sciences (ATAI). Market share data is not yet applicable, given the product is in development stages.
  • Psybrary: This is their drug discovery platform which contains numerous compounds with the potential to become therapeutics. There is no market share associated with this yet. Competitors developing discovery platforms include Recursion Pharmaceuticals (RXRX).

Market Dynamics

industry overview logo Industry Overview

The industry is characterized by high growth potential, but also high risk due to stringent regulatory requirements and clinical trial hurdles. There's a significant unmet need for effective mental health treatments, driving innovation.

Positioning

Enveric is positioned as an innovator in the development of next-generation psychedelic-inspired therapeutics. It aims to distinguish itself through its focus on neuroplasticity and its proprietary drug discovery platform.

Total Addressable Market (TAM)

The global mental health market is expected to reach hundreds of billions of dollars in the coming years. Enveric is positioned to capture a share of this market through the development of novel therapeutics. The precise TAM varies based on the specific indications targeted by its pipeline.

Upturn SWOT Analysis

Strengths

  • Novel therapeutic approach (neuroplastogens)
  • Proprietary drug discovery platform
  • Strong IP portfolio

Weaknesses

  • Early stage development (high risk)
  • Limited financial resources
  • Dependence on regulatory approvals

Opportunities

  • Growing market for mental health treatments
  • Potential for partnerships and collaborations
  • Positive clinical trial results

Threats

  • Regulatory hurdles
  • Competition from larger pharmaceutical companies
  • Clinical trial failures

Competitors and Market Share

competitor logo Key Competitors

  • CMPS
  • ATAI
  • GHRS

Competitive Landscape

Enveric competes with other biotech companies developing psychedelic-inspired therapeutics. Its competitive advantage lies in its unique approach to neuroplasticity and its proprietary drug discovery platform. However, competitors may have greater financial resources and more advanced clinical programs. Market share is currently negligible for all competitors since all are in early stages.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by preclinical research and development progress.

Future Projections: Future growth is dependent on successful clinical trials and potential commercialization of its drug candidates. Analyst estimates vary widely, reflecting the uncertainty inherent in drug development.

Recent Initiatives: Recent initiatives include advancing its EVM201 series into clinical trials and expanding its Psybrary drug discovery platform.

Summary

Enveric Biosciences is a high-risk, high-reward biotech company focusing on innovative mental health treatments. The company's strengths lie in its novel approach and drug discovery platform, but it faces challenges related to funding, regulatory approvals, and clinical trial outcomes. Positive clinical data and strategic partnerships are crucial for its future success. Investors should exercise caution due to the inherent uncertainty in early-stage biotech companies.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings
  • Company Website
  • Industry Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The biotech industry is inherently risky, and past performance is not indicative of future results.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Enveric Biosciences Inc

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 2015-06-24
CEO & Director Dr. Joseph Edward Tucker Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 5
Full time employees 5

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. The company is headquartered in Cambridge, Massachusetts.